Merck Wins FDA Nod for Combo Therapy in Advanced Kidney Cancer

Merck Wins FDA Nod for Combo Therapy in Advanced Kidney Cancer

Source: 
Xconomy
snippet: 


Merck’s blockbuster immunotherapy has notched FDA approval for treating the most serious cases of kidney cancer.

The FDA on Monday approved Merck (NYSE: MRK) drug pembrolizumab (Keytruda) in combination with Pfizer (NYSE: PFE) drug axitinib (Inlyta) as a first-line treatment for advanced renal call carcinoma—kidney cancer that has spread or grown, despite earlier treatments.